The semaglutide cohort ( n = 1470) compared with the non-GLP-1RA anti-obesity medications cohort ( n = 2784) was older, included more women, had a higher prevalence of severe obesity and obesity-associated comorbidities including T2DM and lower prevalence of adverse socioeconomic determinants of health, mental disorders, and substance use disorders
Average body weight reduction in adults taking Semaglutide More effective than diet and exercise alone Weeks of sustained weight loss in clinical trials Patients will provide their medical history and have their lab work drawn
Non-invasive alternative: offers a non-invasive alternative to more aggressive treatments such as Btx injections
Use electrolyte formulas providing 1,000mg+ sodium per serving, taken 1-3 times daily depending on symptoms and activity level
And it seems to me once that happens, if it can simulate the effects we see with the injectables, that would be another big step forward
